Hanneke WM van Laarhoven

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema et al. · The Lancet Oncology · 2018 · 320 citations

Residual Disease, Surgical Oncology, Esophageal Cancer +11

Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response

Marloes Wennemers, Johan Bussink, Blanca Scheijen et al. · Breast Cancer Research · 2011 · 87 citations · Full text

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with <i>IDH1</i> -mutated or <i>IDH2</i> -mutated solid tumours

Remco J. Molenaar, Robert J.S. Coelen, Mohammed Khurshed et al. · BMJ Open · 2017 · 79 citations · Full text

Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients’ preferences

Inge Henselmans, Hanneke WM van Laarhoven, Jane Van der Vloodt et al. · Palliative Medicine · 2016 · 68 citations

High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1

Anne Steins, Madelaine G. van Mackelenbergh, Amber P. van der Zalm et al. · EMBO Reports · 2020 · 39 citations · Full text